Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget's mammary disease

Journal of the American Academy of Dermatology

Volumn 55, Issue 1, 2006, Pages 75-79

  Sanchez Carpintero, Ignacio ^a,b   Martínez, Maria I ^c   Mihm Jr , Martin C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Clinica Las Americas   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CYTOTOXICITY; DRUG EFFICACY; ECZEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HELPER CELL; HEMANGIOENDOTHELIOMA; HUMAN; MALAISE; MAST CELL; NAUSEA; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; T LYMPHOCYTE; TUMOR REGRESSION; VASCULAR TUMOR;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FACIAL NEOPLASMS; FEMALE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; MIDDLE AGED; PAGET'S DISEASE, MAMMARY;

EID: 33744986969     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.01.056     Document Type: Article

References (22)

1. Dahl M.V. Imiquimod: an immune response modifier. J Am Acad Dermatol 43 (2000) 1-5
2. Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., Fuller A.E., et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218 (2002) 74-86
3. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
4. Szeimies R.M., Gerritsen M.J., Gupta G., Ortonne J.P., Serresi S., Bichel J., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 51 (2004) 547-555
5. Geisse J., Caro I., Lindholm J., Golitz L., Stampone P., and Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50 (2004) 722-733
6. Zampogna J.C., Flowers F.P., Roth W.I., and Hassenein A.M. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 47 Suppl (2002) S229-S235
7. Ahmed I., and Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143 (2000) 843-845
8. Wolf I.H., Smolle J., Binder B., Cerroni L., Richtig E., and Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139 (2003) 273-276
9. Gerdsen R., Wenzel J., Uerlich M., Bieber T., and Petrow W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 205 (2002) 416-418
10. Agarwal S., and Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 146 (2002) 338-339
11. Buates S., and Matlashewski G. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother 45 (2001) 1137-1142
12. Hengge U.R., and Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 30 (2004) 1101-1112
13. Martínez M.I., Sanchez-Carpintero I., North P.E., and Mihm Jr. M.C. Infantile hemangioma: a clinical resolution with imiquimod 5% cream. Arch Dermatol 138 (2002) 881-884
14. Takahashi K., Mulliken J.B., Kozakewich H.P., Rogers R.A., Folkman J., and Ezekowitz R.A. Cellular markers that distinguish the phase of hemangioma during infancy and chilhood. J Clin Invest 93 (1994) 2357-2364
15. Sidbury R., Neuschler N., Neuschler E., Sun P., Wang X.Q., Miller R., et al. Topical applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 121 (2003) 1205-1209
16. Schon M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138-1149
17. Razon M.J., Kraling B.M., Mulliken J.B., and Bischoff J. Increased apoptosis coincides with onset of involution of infantile hemangioma. Microcirculation 5 (1998) 189-195
18. Majewski S., Marczak M., Mlynarczyk B., Benninghoff B., and Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 44 (2005) 14-19
19. Latti S., Leskinen M., Shiota N., Wang Y., Kovanen P.T., and Lindstedt K.A. Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression. J Cell Physiol 195 (2003) 130-138
20. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114 (2000) 135-141
21. Tomai M.A., Imbertson L.M., Stanczak T.L., Tygrett L.T., and Waldschmidt T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203 (2000) 55-65
22. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., et al. Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34